BR112021026214A2 - Método para tratamento de fibrose pulmonar idiopática - Google Patents

Método para tratamento de fibrose pulmonar idiopática

Info

Publication number
BR112021026214A2
BR112021026214A2 BR112021026214A BR112021026214A BR112021026214A2 BR 112021026214 A2 BR112021026214 A2 BR 112021026214A2 BR 112021026214 A BR112021026214 A BR 112021026214A BR 112021026214 A BR112021026214 A BR 112021026214A BR 112021026214 A2 BR112021026214 A2 BR 112021026214A2
Authority
BR
Brazil
Prior art keywords
pulmonary fibrosis
idiopathic pulmonary
treatment
polymorph
stereoisomer
Prior art date
Application number
BR112021026214A
Other languages
English (en)
Inventor
Hongjun Wang
Jing Li
Jing Zhao
Liying Zhou
Weina Liu
Weiting Zhong
Yanan Liu
Yanping Zhao
Yuanyuan Jiang
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of BR112021026214A2 publication Critical patent/BR112021026214A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

método para tratamento de fibrose pulmonar idiopática. a presente invenção refere-se a um método para prevenção, alívio e/ou tratamento de fibrose pulmonar idiopática, que compreende administrar uma quantidade eficaz de um composto representado pela fórmula (i), ou um sal farmaceuticamente aceitável, éster, estereoisômero, polimorfo, solvato, n-óxido, composto rotulado com isótopo, metabólito ou profármaco do mesmo a um indivíduo em necessidade do mesmo.
BR112021026214A 2019-06-25 2020-06-24 Método para tratamento de fibrose pulmonar idiopática BR112021026214A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019092675 2019-06-25
PCT/CN2020/097881 WO2020259528A1 (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Publications (1)

Publication Number Publication Date
BR112021026214A2 true BR112021026214A2 (pt) 2022-02-15

Family

ID=74061495

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026214A BR112021026214A2 (pt) 2019-06-25 2020-06-24 Método para tratamento de fibrose pulmonar idiopática

Country Status (11)

Country Link
US (1) US20220233538A1 (pt)
EP (1) EP3992183A4 (pt)
JP (1) JP2022539329A (pt)
KR (1) KR20220029681A (pt)
CN (1) CN114026072A (pt)
AU (1) AU2020305979A1 (pt)
BR (1) BR112021026214A2 (pt)
CA (1) CA3144113A1 (pt)
IL (1) IL289192A (pt)
TW (1) TWI804743B (pt)
WO (1) WO2020259528A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996922A (zh) * 2020-08-31 2023-04-21 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
CN118019530A (zh) * 2021-09-17 2024-05-10 北京泰德制药股份有限公司 治疗病毒感染的方法
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
WO2023088231A1 (zh) * 2021-11-16 2023-05-25 北京泰德制药股份有限公司 一种rock2抑制剂的纳米晶制剂及其制备方法
WO2023134688A1 (zh) * 2022-01-13 2023-07-20 武汉朗来科技发展有限公司 一种rock抑制剂的盐及盐的晶型、组合物和药物用途
WO2024078553A1 (zh) * 2022-10-13 2024-04-18 北京泰德制药股份有限公司 治疗尘肺病的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3262041A4 (en) * 2015-02-27 2018-08-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
AR110401A1 (es) * 2016-12-21 2019-03-27 Chiesi Farm Spa Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa
EP3647311B1 (en) * 2017-06-30 2023-11-01 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
KR102563325B1 (ko) * 2017-06-30 2023-08-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도

Also Published As

Publication number Publication date
TWI804743B (zh) 2023-06-11
KR20220029681A (ko) 2022-03-08
US20220233538A1 (en) 2022-07-28
TW202114679A (zh) 2021-04-16
JP2022539329A (ja) 2022-09-08
IL289192A (en) 2022-02-01
CA3144113A1 (en) 2020-12-30
AU2020305979A1 (en) 2022-02-17
EP3992183A4 (en) 2023-06-21
EP3992183A1 (en) 2022-05-04
CN114026072A (zh) 2022-02-08
WO2020259528A1 (zh) 2020-12-30

Similar Documents

Publication Publication Date Title
BR112021026214A2 (pt) Método para tratamento de fibrose pulmonar idiopática
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
NZ721645A (en) Compounds for use as gpr120 agonists
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
MX2018015302A (es) Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
WO2016085939A3 (en) Compounds and methods of treating ocular disorders
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
BR112013028095A2 (pt) inibidores de csf-1r para o tratamento de tumores cerebrais
BR112021017354A2 (pt) Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
BR112016024473A2 (pt) composto, composição farmacêutica, e, método para tratamento de uma doença e/ou condição
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2022000154A (es) Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos.